The coexistence of chronic myeloid leukaemia(CML) and chronic lymphocytic leukemia(CLL) has been reported occasionally in literature, with only seven cases of simultaneous occurrence of these two diseases. We present here a case of 57 yr male patient where a complete blood count and differential done using volume conductivity scatter (VCS) technology suggested a diagnosis of CML with CLL. It was further confi rmed by immunophneotyping and cytogenetic analysis. The patient was started on tyrosine kinase inhibitor, 400 mg once daily. Four months after the treatment, patient is doing fi ne with a count of 22 × 10 9 /L and 64% lymphocytes.
INTRODUCTION
The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) is an uncommon event with only 21 cases reported in literature until date. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] These two diseases can occur either sequentially, or simultaneously as in the present case. High risk of developing a second malignancy associated with an immune modulation and associated therapeutic regimen, have been proposed as the cause for sequential development of these diseases. For simultaneous occurrence, a possibility of common stem cell origin for these two diseases has been suggested. The first investigation to be done in these cases is a complete blood count (CBC) with differential leukocyte count (DLC). Automated analyzers can indicate the presence of a proliferative neoplasm with a suggestion of myeloid or lymphoid origin. In addition, they can very well predict the morphology of the neoplastic cells. We present here a case of 57-year-old male patient who presented to us with a weakness and an abdominal discomfort. CBC done with the automated analyzer using VCS technology for differential suggested a proliferative neoplasm with both myeloid and lymphoid component. Morphological examination of peripheral smears and bone marrow along with immunophenotypic finding and cytogenetic analysis confirmed the simultaneous occurrence of CML and CLL in this case.
CASE REPORT
We report a case of a 57-year-old male, diabetic, normotensive patient presented to us with the complaint of weakness and an abdominal discomfort for 15 days. On examination, pallor was present but no icterus. Splenomegaly was seen, which was 3 cm below the costal margin. No lymphadenopathy or any other significant findings were noted. CBC done with automated analyzer using VCS technology for the differential count showed a hemoglobin of 102 g/L, total leukocyte count of 131  10 9 /L, platelet count of 436  10 9 /L. DLC given by the analyzer was polymorphs-66.7, lymphocytes-26.6, monocytes-3.0, basophil-2.2, eosinophil-0.5. The mean volume of lymphocytes was lower than that of the control group (60 vs. 78 $ ) with little variation in size, as indicated by slightly higher standard deviation of volume index (SDVI). Similarly, the mean volume of neutrophils was also increased (172.8 vs. 149.2 $ ) with very high SDVI, indicating the presence of the whole spectrum of immature myeloid cells. Analyzing all these findings, we concluded that we were dealing with a proliferative disorder which was both myeloid as well as lymphoid and showed the presence of myeloid precursor, basophils and small sized lymphoid cells. Peripheral smear shows the presence of leukocytosis with the shift to left and basophilia. Lymphocytosis was also noted, $ Mean volume of lymphocytes and neutrophils were evaluated using the values from age and gender matched 30 healthy blood donors. After an extensive search, only 21 cases with a concurrent occurrence of CML and CLL could be found in the literature. Most of the cases have CLL preceding CML (n = 11) with an interval between the two diseases ranging from 2 months to 84 months.
Cases with simultaneous are less frequent (n = 7). Three cases of CLL following CML by duration ranging from 20 to 74 months have been reported. A brief account of these cases has been mentioned in [ Table 1 ].
The present case has leukocytosis at presentation with 30% of lymphocytes and shift to left. Automated analyzer with VCS technology for the differential count directed us to perform ancillary investigation to prove the co-existence of these two diseases. CML was the obvious finding, but the nature of lymphocytosis was to be determined. VCS parameters of a low mean volume with a slightly higher SDVI suggested the neoplastic nature of the lymphocytes. As suggested by Silva et al. [25] these findings favor a CLL over reactive lymphocytosis. Peripheral smear, bone marrow aspirate, bone marrow biopsy, immunophenotypic evaluation and cytogenetic which was of small size and showed the presence of hypercondensed chromatin. Bone marrow examination showed the presence of hypercellular packed particles with cellular trails. There was myeloid preponderance, shift to left and basophilia with a myeloid erythroid ratio of 30:1. Micromegakaryocytes were seen along with occasional sea blue histiocytes. An additional finding was the presence of approximately 30% small-sized atypical lymphoid cells with hyper-condensed chromatin. Bone marrow biopsy showed a hypercellular marrow with 95% of cellularity showing myeloid and megakaryocytic preponderance. Two CD20 positive lymphoid nodules were noted [ Figure 1 ]. Immunophenotypic analysis by flow cytometry was performed on peripheral blood which showed the presence of 31% lymphoid cells with co expression of CD19, CD5, CD23 and FMC 7 negativity [ Figure 2 ]. Conventional karyotype done on bone marrow sample showed t(9;22)(q34;q11), Philadelphia positive.
Based on all the above findings, a final diagnosis of concurrent CML and CLL was made. Patient was started on a tyrosine kinase inhibitor (imatinib) in a dose of 400 mg OD. Patient is on regular follow-up and is doing fine with a count of 22  10 9 /L and 64% lymphocytes.
DISCUSSION
Coexistence of myeloproliferative and lymphoproliferative disorders in the same patient is uncommon. Even rare is the concordant occurrence of CML and CLL which can be found as isolated case reports in the literature. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Leukemogenic effect of therapy and an impaired immune response in cases of CLL have been suggested as the possible risk factors for development of second malignancy. [21] Although the second malignancy is usually a non-hematological one, association with other hematological neoplasm has also been reported. On the other hand, patients with CML have a natural history of developing a blast crisis and are rarely associated with the development of a second malignancy. However, it has also been documented that BCR-ABL transformed cells secrete cytokines like IL3 which increases the production of B lymphoid cells from human CD34 + /CD38  progenitor cells and in turn may lead to the development of CLL. [22] These probable explanations do not hold true for the cases where these two chronic neoplasms have occurred simultaneously without any prior history of one or the other disease. In such a situation, the concordant occurrence can either be a coincidental finding, or it can be presumed that these neoplasms originate from a unique stem cell capable of differentiating into two different cell lines. Molecular studies aimed at ascertaining such a possibility are scarce and have found the separate origins of these two diseases. BCR/ABL rearrangement could be detected in granulocytic component only, but not in the mononuclear cell fraction, probably composed mainly of CLL cells. On the contrary, characteristic band corresponding to a monoclonal lymphoid population after JH rearrangement analysis could be seen in the lymphoid-enriched cellular component, but not in the myeloid fraction. [2, 23, 24] Leoni et al. [1] 55 M Simultaneous Maher et al. [2] 69 M Simultaneous Crescenzi et al. [3] 64 M Simultaneous Vilpo et al. [4] 58 M Simultaneous Esteve et al. [5] 71 F Simultaneous Mansat-De Mas et al. [6] 68 M Simultaneous Katović et al. [7] 55 M Simultaneous Present case (2012) 55 M Simultaneous CML following CLL Khojasteh et al. [8] 55 M 61 Months Faguet et al. [9] 83 M 2 Months Teichmann et al. [10] 47 M 72 Months Whang-Peng et al. [11] 62 M 36 Months Whang-Peng et al. [11] 74 M 24 Months Schreiber et al. [12] 55 M 84 Months Hashimi et al. [13] 82 F 60 Months Nanjangud et al. [14] 43 M 73 Months Mossafa et al. [15] 76 F 12 Months Ramanarayanan et al. [16] 52 F 29 Months Hatt ori et al. [17] 68 F 24 Months CLL following CML Salim et al. [18] 54 F 36 Months Gargallo et al. [19] 88 F 20 Months Bhagavathi et al. [20] 
CONCLUSION
Our case is an addition to the scarce literature on concurrent occurrence of CML and CLL which can be either sequential or simultaneous. IPA, cytogenetic and molecular analysis of these cases has revealed a rare event of leukemogenesis caused by a biclonal evolution. In addition, our report points out the importance of automated CBC analyzer with VCS parameter in preliminary diagnosis where this rare possibility can be suggested and ancillary investigation advised for further work-up.
